Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Amgen stock falls
Amgen dismisses bone density concerns related to its weight-loss drug
Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after those concerns wiped off more than $12 billion from the company's market value.
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density
On Tuesday, a Cantor analyst wrote that additional data from Amgen’s experimental weight loss injection, MariTide, suggests a new potential safety risk tied to the drug. On Wednesday, Amgen Inc (NASDAQ:AMGN) stated the MariTide (maridebart cafraglutide,
Amgen stock falls as analysts mull over weight loss drug's bone density data
Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone mineral density over 12 weeks.
1d
What’s Happening With Amgen Stock?
In this photo illustration, Amgen logo is displayed on a smartphone with a S&P ... [+] index website background. (Photo ...
23h
Amgen Rebounds. But Do Eli Lilly And Viking Therapeutics Now Have The Upper Hand?
Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral ...
1d
Amgen slips as Cantor cites safety concerns linked to obesity candidate
Amgen (AMGN) stock falls as Cantor Fitzgerald raises safety concerns over bone mineral density loss linked to obesity ...
20h
Signal Says Pharma Stock Selloff Should Be Over
Shares of pharmaceutical giant Amgen (AMGN) are attempting to bounce back after suffering a steep drop of 7.1% yesterday.
devdiscourse
3h
Innovations and Challenges in Pharma: A Global Health Report
This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...
Hosted on MSN
1d
Amgen dismisses bone density concerns related to its new weight-loss drug
(Reuters) -
Amgen
said on Wednesday there was no link between its experimental
weight
-
loss
drug and changes in bone ...
Investor's Business Daily on MSN
1d
Amgen Drops 7% After A 'Big Unknown Risk' Rattles Its Monthly Obesity Shot
Amgen stock tumbled late Tuesday on a report that its high-profile weight-loss shot, MariTide, could be linked to bone ...
devdiscourse
18h
Global Health Challenges: From Weight-Loss Wars to Vaccine Shortages
A roundup of top health news highlights Novo Nordisk's $16.5 billion deal scrutiny, Amgen's weight-loss drug controversy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback